Antiphospholipid antibody syndrome

Hematology

Volumn 10, Issue SUPPL. 1, 2005, Pages 33-38

  Diz Küçükkaya, Reyhan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; HEPARIN; HYDROXYCHLOROQUINE; PHENOTHIAZINE; PHENYTOIN; PHOSPHOLIPID ANTIBODY; PROCAINAMIDE; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; BLEEDING; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LEPROSY; NEPHROTIC SYNDROME; PREGNANCY; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SYPHILIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOPHILIA; THROMBOSIS; VEIN THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; DISEASE MANAGEMENT; FEMALE; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOCYTOPENIA; THROMBOSIS;

EID: 29244492281     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330512331389845     Document Type: Review

References (68)

1. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999;42:1309-1311.
2. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Eng J Med 2002;346:752-763.
3. Hanly JG. Antiphospholipid syndrome: an overview. CMAJ 2003;168:1675-1982.
4. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999;353:1348-1353.
5. Goodnight SH. Antiphospholipid antibodies and thrombosis. Curr Op Hematol 1994;1:354-361.
6. Santoro SA. Antiphospholipid antibodies and thrombotic predisposition: Underlying pathogenetic mechanisms. Blood 1994;83:2389-2391.
7. Greaves M, Cohen H, Machin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000;109:704-715.
8. Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2000;43:440-443.
9. Asherson RA. A 'primary' antiphospholipid syndrome? J Rheumatol 1998;15:1742-46.
10. Nimmo MC, Carter CJ. The antihospholipid antibody syndrome: a riddle wrapped in a mystery inside an enigma. Clin Applied Immunol Rev 2003;4:125-140.
11. Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74:1-9.
12. McNeil HP, Chesterman CN, Kirilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991;49:193.
13. Brandt JT, Triplett DA, Alving B, Scharer I. Criteria for the diagnosis of lupus anticoagulants: An update. Thromb Haemost 1995;74:1185-1187.
14. McNeil P, Simpson R, Chesterman C, Kirilis S. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-GPI (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120-4124.
15. Galli M, Comfurius P, Maassen C. Anticardiolipin antibodies (ACA) directed not to cardiolipin but a plasma protein cofactor. Lancet 1990;335:1544-1545.
16. Galli M. Should we include anti-prothrombin antibodies in the screening for the antiphospholipid syndrome? J Autoimmun 2000;15:101-105.
17. Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA 1999;96:5164-68.
18. Pierangeli S, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris N. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999;99:1997-2002.
19. Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001;88:245-50.
20. Meroni PL, Raschi E, Camera M, et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestation of the syndrome. J Autoimmun 2000;15:237-40.
21. Combes V, Simon A, Grau G, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999;104: 93-102.
22. Mercanoglu F, Erdogan D, Oflaz H, et al. Impaired branchial endothelial function in patients with primary anti-phospholipid syndrome. Int J Clin Pract 2004;58:1003-7.
23. Williams FMK, Jurd K, Hughes GRV, Hunt BJ. Antiphospholipid syndrome patients' monocytes are 'primed' to express tissue factor. Thromb Haemost 1998;80:864-5.
24. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-1173.
25. Ames PRJ, Tommasino C, D'Andrea G, et al. Thrombophilic genotypes in subjects with idiophatic antiphospholipid antibodies. Prevalance and significance. Thromb Haemost 1998; 79:46.
26. 506→Gln mutation in patients with antiphospholipid antibodies. Lupus 1996;5:303.
27. Hansen KE, Kong DF, Moore KD, Ortel TL. Risk factors associated with thrombosis in patients with antiphospholipid antibodies. J Rheumatol 2001;28:2018.
28. Chopra N, Koren S, Greer WL, et al. Factor V Leiden, prothrombin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies. J Rheumatol 2002;29: 1683-1688.
29. Galli M, Finazzi G, Duca F, Norbis F, Moia M. The G1691-A mutation of factor V, not the G20210-A mutation of factor II or the C677-T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with venous thrombosis in patients with lupus anticoagulants. Br J Haematol 2000;108:865-870.
30. Forasterio R, Martinuzzo M, Adamczuk Y, Varela MLI, Pombo GV, Carreras LO. The combination of thrombophilic genotypes is associated with definite antiphospholipid syndrome. Haematologica 2001;86:735.
31. Alarcon-Segovia D, Ruiz-Arguelles GJ, Garces-Eisele J, Ruiz-Arguelles A. Inherited activated protein C resistance in a patient with familial primary antiphospholipid syndrome. J Rheumatol 1996;23:2162.
32. Diz-Kucukkaya R, Demir K, Yenerel MN, Nalçaci M, Kaymakoǧlu S, İnanç M. Coexistence of homozygous factor V Leiden mutation and antiphospholipid antibodies in two patients presented with Budd-Chiari syndrome. Haematologia 2002;32:2061.
33. Dizon-Tawson D, Hutchinson C, Silver R, Branch W. The factor V Leiden mutation which predispose to thrombosis is not common in patients with antiphospholipid syndrome. Thromb Haemost 1995;74:1029.
34. Diz-Kucukkaya R, Hançer VS, İnanç M, Nalçaci M, Pekçelen Y. Factor XIII Val34Leu polymorphism does not contibute to the prevention of thrombotic complications in patients with antiphospholipid syndrome. Lupus 2004;13:32-35.
35. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992;19:508.
36. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome :Clues to pathogenesis from series of 80 patients. Medicine (Baltimore) 2001;80:355.
37. Galli M, Finazzi G, Barbui T. Thrombocytopenia in the antiphospholipid syndrome. Br J Med 1996;93:1-6.
38. Italian Registry of Antiphospholipid Antibodies (IR-APA). Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to systemic lupus erythematosus): First report from the Italian registry. Haematologica 1993;78:313.
39. Cuadrado MJ, Mujic F, Munoz E, Khamashta MA, Hughes GRV. Thrombocytopenia in the antiphospholipid syndrome. Ann Rheum Dis 1997;56:194.
40. Harris EN. Annotation: antiphospholipid antibodies. Br J Haematol 1990;74:1.
41. Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 2001;98:1760-1764.
42. Godeau B, Piette JC, Fromont P, Intrator L, Schaeffer A, Bierling A. Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome. Br J Haematol 1997;98:873.
43. Macchi L, Rispal P, Clofent-Sanchez G, et al. Antiplatelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia. Br J Haematol 1997;98:336.
44. Galli M, Daldossi M, Barbui T. Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1994;71:571.
45. Lipp E, von Felten A, Sax H, Muller D, Berchtold P. Antibodies against platelet glycoproteins and antiphospholipid antibodies in autoimmune thrombocytopenia. Eur J Haematol 1998;60:283.
46. Stasi R, Stipa E, Oliva F, et al. Prevalance and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 1994;84: 4203.
47. Fabris F, Steffan A, Cordiano I, et al. Specific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopenia. Eur J Haematol 1994;53:232.
48. Bernini JC, Buchanan GR, Ashcraft J. Correction of hypoprothrombinemia and severe hemorrhage associated with a lupus anticoagulant. J Pediatr 1993;123:937.
49. Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic thrombocytopenic purpura. Am J Med 1995;98:436.
50. Font J, Jimenez S, Cervera R, et al. Splenectomy for refractory Evans' syndrome associated with antiphospholipid antibodies: report of two cases. Ann Rheum Dis 2000;59:920.
51. Hakim AJ, Machin SJ, Isenberg DA. Autoimmune thrombocytopenia in primary antiphospholipid syndrome and systemic lupus erythematosus: The response to splenectomy. Semin Arthritis Rheum 1998;28:20.
52. Alarcon-Segovia D, Sanchez-Guerrero J. Correction of thrombocytopenia with small dose aspirin in the primary antiphospholipid syndrome. J Rheumatol 1989;16:1359.
53. Alliot C, Messouak D, Albert F. Correction of thrombocytopenia with aspirin in the primary antiphospholipid syndrome. Am J Hematol 2001;68:215.
54. Wisbey HL, Klestov AC. Thrombocytopenia corrected by warfarin in antiphospholipid syndrome. J Rheumatol 1996;23: 769.
55. Ames PRJ, Orefice G, Brancaccio V. Reversal of thrombocytopenia following oral anticoagulation in two patients with primary antiphospholipid syndrome. Lupus 1995;4:491.
56. Suarez MI, Diaz RA, Aguayo-Canela D, Pujol de la Llave. Correction of severe thrombocytopenia with chloroquine in the primary antiphospholipid syndrome. Lupus 1996;5:81.
57. Petri M. Epidemiology of antiphospholipid antibody syndrome. J Autoimmun 2000;15:145-151.
58. Gezer S. Antipholipid syndrome. Dis Mon 2003;49:696-74.
59. Lockshin MD, Erkan D. Treatment of the antiphospholipid syndrome. N Eng J Med 2003;349:1177-1179.
60. Erkan D, Merrill JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD. High risk of thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 2001;44:1466-1467.
61. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort. Effects on lipids, glucose, and thrombosis. Lupus 1996;5(supp 1):S16-22.
62. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Eng J Med 1995;332:993-997.
63. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992;117:303-308.
64. Derksen RH, de Groot PG, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 1993;52:689-692.
65. Prandoni P, Simioni P, Girolami A. Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin coagulation. Thromb Haemost 1996;75:859.
66. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998;104:332-338.
67. Ames PR, Ciampa A, Margaglione M, Scenna G, Iannaccone L, Brancaccio V. Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation: an 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia. Thromb Haemost 2005;93: 694-9.
68. The WARSS, APASS, PICSS, HAS and GENESIS study groups. The feasibility of a collaborative double-blind study using an anticoagulant. Cerebrovasc Dis 1997;7:100-112.